Is the combination of Cetuximab with chemo-radiotherapy regimens worthwhile in the treatment of locally advanced head and neck cancer? A review of current evidence

Critical Reviews in Oncology/Hematology

Volumn 85, Issue 2, 2013, Pages 112-120

  Numico, Gianmauro ^a   Franco, Pierfrancesco ^b   Cristofano, Antonella ^a   Migliaccio, Fernanda ^b   Spinazzé, Silvia ^a   Silvestris, Nicola ^c   Cante, Domenico ^d   Sciacero, Piera ^d   La Porta, Maria Rosa ^d   Girelli, Franco ^d   Ricardi, Umberto ^e  

^a Spedale U Parini   (Italy)

^b Ospedale Regionale U Parini   (Italy)

^c NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^d Ospedale di Ivrea   (Italy)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

Cetuximab; Chemo radiotherapy; EGFR; Head and neck

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; HYDROXYUREA; PACLITAXEL; PEMETREXED;

ADVANCED CANCER; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CHEMORADIOTHERAPY; DIARRHEA; DOSAGE SCHEDULE COMPARISON; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPHAGIA; ELECTROLYTE DISTURBANCE; FEASIBILITY STUDY; FEBRILE NEUTROPENIA; GASTROINTESTINAL HEMORRHAGE; HEAD AND NECK CANCER; HUMAN; HYPOMAGNESEMIA; INDUCTION CHEMOTHERAPY; INFUSION RELATED REACTION; METASTASIS; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NASOPHARYNX CANCER; NEUTROPENIA; ORAL MUCOSITIS; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; REVIEW; SEPSIS; SKIN TOXICITY; STOMATITIS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM STAGING; PROGNOSIS;

EID: 84872610898     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.05.005     Document Type: Review

References (46)

1. Pignon J.P., le Maître A., Maillard E., Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiotherapy and Oncology 2009, 92:4-14. on behalf of the MACH-NC Collaborative Group.
2. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. New England Journal of Medicine 2006, 354:567-578.
3. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. New England Journal of Medicine 2008, 359:1116-1127.
4. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. New England Journal of Medicine 2007, 357:1705-1715.
5. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. New England Journal of Medicine 2007, 357:1695-1704.
6. Pointreau Y., Garaud P., Chapet S., et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. Journal of the National Cancer Institute 2009, 101:498-506.
7. Argiris A., Karamouzis M.V. Empowering induction therapy for locally advanced head and neck cancer. Annals of Oncology 2011, 22:773-781.
8. Hitt R., Lopez-Pousa A., Martinez-Trufero J., et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. Journal of Clinical Oncology 2005, 23:8636-8645.
9. Haddad R.I., Tishler R.B., Norris C., et al. Phase I study of C-TPF in patients with locally advanced squamous cell carcinoma of the head and neck. Journal of Clinical Oncology 2009, 27:4448-4453.
10. Mesia R., Rueda A., Vera R., et al. Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial. Journal of Clinical Oncology 2009, 27(15S):6014.
11. Vokes E.E., Stenson K., Rosen F.R., et al. Weekly carboplatin and paclitaxel followed by concomitant paclitaxel, fluorouracil, and hydroxyurea chemoradiotherapy: curative and organ-preserving therapy for advanced head and neck cancer. Journal of Clinical Oncology 2003, 21:320-326.
12. Kies M.S., Holsinger F.C., Lee J.J., et al. Induction chemotherapy and Cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial. Journal of Clinical Oncology 2010, 28:8-14.
13. Rampino M., Bacigalupo A., Russi E., et al. Efficacy and feasibility of induction chemotherapy and radiotherapy plus cetuximab in head and neck cancer. Anticancer Research 2012, 32(1):195-199.
14. Lefebvre J., Pointreau Y., Rolland F., et al. Groupe Oncologie Radiotherapie Tete Et Cou (GORTEC). Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study. Journal of Clinical Oncology 2009, 27(15S):6010.
15. Argiris A., Heron D.E., Smith R.P., et al. Induction docetaxel, cisplatin, and cetuximab followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locally advanced head and neck cancer. Journal of Clinical Oncology 2010, 28:5294-5300.
16. Wanebo H.J., Ghebremichael M.S., Burtness B., et al. Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: primary site organ preservation and disease control at 2 years (ECOG, E2303). Journal of Clinical Oncology 2010, 28(15S):5513.
17. Seiwert T.Y., Haraf D.J., Cohen E.E., et al. A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC). Journal of Clinical Oncology 2011, 29(15S):5519.
18. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. New England Journal of Medicine 2003, 349(22):2091-2098.
19. Bernier J., Domenge C., Ozsahin M., et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. New England Journal of Medicine 2004, 350:1945-1952.
20. Pfister D.G., Su Y.B., Kraus D.H., et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm. Journal of Clinical Oncology 2006, 24:1072-1078.
21. Langer C.J., Lee J.W., Patel U.A., et al. Preliminary analysis of ECOG 3303. Concurrent radiation (RT), cisplatin (DDP) and cetuximab (C) in unresectable, locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN). Journal of Clinical Oncology 2008, 26(15S):6006.
22. Kuhnt T., Sandner A., Wendt T., et al. Phase I trial of dose-escalated cisplatin with concomitant cetuximab and hyperfractionated-accelerated radiotherapy in locally advanced squamous cell carcinoma of the head and neck [Internet]. Annals of Oncology 2010, 21:2284-2289.
23. Ma B.B.Y., Kam M.K.M., Leung S.F., et al. A phase II study of concurrent cetuximab-cisplatin and intensity-modulated radiotherapy in locoregionally advanced nasopharyngeal carcinoma. Annals of Oncology 2012, 23:1287-1292.
24. Ang K.K., Zhang Q.E., Rosenthal D.I., et al. A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC). Journal of Clinical Oncology 2011, 29S:5500.
25. Kao J., Policarpio L., Teng M., Burri R., Genden E., Packer S. Phase II trial of concurrent 5-fluorouracil, hydroxyurea, cetuximab, and intensity modulated radiation therapy (IMRT) for locally advanced head and neck cancer. Journal of Clinical Oncology 2009, 27(15S):6014.
26. Argiris A., Karamouzis M.V., Smith R., et al. Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer. Annals of Oncology 2011, 22:2422-2488.
27. Merlano M., Russi E., Benasso M., et al. Cisplatin-based chemoradiation plus cetuximab in locally advanced head and neck cancer: a phase II clinical study. Annals of Oncology 2011, 22:712-717.
28. Merlano M. Alternating chemotherapy and radiotherapy in locally advanced head and neck cancer: an alternative?. Oncologist 2006, 11(2):146-151.
29. Lefebvre J.L., Rolland M., Tesselaar M., et al. Phase III randomized trial on larynx preservation comparing sequential versus alternating chemotherapy and radiotherapy. Journal of the National Cancer Institute 2009, 101:142-152.
30. Benasso M., Corvo R., Ponzanelli A., et al. Alternating gemcitabine and Cisplatin with gemcitabine and radiation in stage IV squamous cell carcinoma of the head and neck. Annals of Oncology 2004, 15:646-652.
31. Numico G., Russi E.G., Vitiello R., et al. Gemcitabine and cisplatin in a concomitant alternating chemoradiotherapy program for locally advanced head-and-neck cancer: a pharmacology-guided schedule. International Journal of Radiation Oncology, Biology, Physics 2006, 66:731-737.
32. Maughan T.S., Adams R.A., Smith C.G., et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3MRC COIN trial. Lancet 2011, 377:2103-2114.
33. Pirker R., Pereira J.R., Szczesna A., et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009, 373:1525-1531.
34. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyper fractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. New England Journal of Medicine 1998, 338:1798-1804.
35. Wendt T.G., Grabenbauer G.G., Rodel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. Journal of Clinical Oncology 1998, 16:1318-1324.
36. Adelstein D.J., Lavertu P., Saxton J.P., et al. Mature results of a phase III randomized trial comparing concurrent chemoradiotherapy with radiation therapy alone in patients with stage III-IV squamous cell carcinoma of the head and neck. Cancer 2000, 88:876-883.
37. Argiris A., Brockstein B., Haraf D.J., et al. Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clinical Cancer Research 2004, 10:1956-1962.
38. Adelstein D.J., Saxton J.P., Rybicki L.A., et al. Multiagent concurrent chemoradiotherapy for locoregionally advanced squamous cell head and neck cancer: mature results from a single institution. Journal of Clinical Oncology 2006, 24:1064-1071.
39. Mell L.K., Dignam J.J., Salama J.K., et al. Predictors of competing mortality in advanced head and neck cancer. Journal of Clinical Oncology 2009, 28:15-20.
40. Formenti S.C., Demaria S. Effects of chemoradiation on tumor-host interactions: the immunologic side. Journal of Clinical Oncology 2008, 26:1582-1583.
41. Pinto C., Barone C.A., Girolomoni G., et al. Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 2011, 16:228-238.
42. Shrag D., Chung K.Y., Flombaum C., Saltz L. Cetuximab Therapy and Symptomatic hypomagnesemia. Journal of the National Cancer Institute 2005, 97:1221-1224.
43. Izzedine H., Bahleda R., Khayat D., et al. Electrolyte disorders related to EGFR-targeting drugs. Critical Reviews in Oncology - Hematology 2010, 73:213-219.
44. Numico G., Silvestris N., Russi E.G. Advances in EGFR-directed therapy in head and neck cancer. Frontiers in Bioscience 2011, S3:454-466.
45. Burtness B., Goldwasser M.A., Flood W., Mattar B., Forastiere A.A. Phase III randomized trial of cisplatin plusplacebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. Journal of Clinical Oncology 2005, 23:8646-8654.
46. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy pluscetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncology 2010, 11:21-28.